PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

McDonagh M. Drug Class Review: Disease-Modifying Drugs for Multiple Sclerosis: Single Drug Addendum: Fingolimod: Final Original Report [Internet]. Portland (OR): Oregon Health & Science University; 2011 Feb.

Evidence Tables

Evidence Table 1. Data abstraction of fingolimod trials

Evidence Table 2. Quality assessment of fingolimod trials

Abbreviations used in evidence tables

AbbreviationMeaning
ACTActive-control trial
AEAdverse event
ALTAlanine aminotransferase
ANCOVAAnalysis of covariance
ANOVAAnalysis of variance
ARRAnnualized relapse rate
bidTwice daily
BMIBody mass index
CCTControlled clinical trial
CIConfidence interval
CNSCentral nervous system
CRControlled release
CVCardiovascular
CVSCardiovascular system
dDay
DBDouble-blind
dLDeciliter
ECGElectrocardiogram
EDSSExpanded Disability Status Scale
EEGElectroencephalogram
EFEjection fraction
ERExtended release
FDAUS Food and Drug Administration
FUFollow-up
gGram
GIGastrointestinal
GPGeneral practitioner
hHour
HDL-CHigh density lipoprotein cholesterol
HMOHealth maintenance organization
HRHazard ratio
HRQOLHealth-related quality of life
ICD-10International Classification of Diseases, Tenth Revision
ICD-9International Classification of Diseases, Ninth Revision
IRImmediate release
ITTIntention-to-treat
LLiter
LALong acting
LDL-CLow-density lipoprotein cholesterol
LOCFLast Observation Carried Forward
LS meansLeast squares means
MANCOVAMultivariate analysis of covariance
mcgMicrogram
mgMilligram
minMinute
mLMilliliter
moMonth
MSMultiple sclerosis
MSFCMultiple Sclerosis Functional Composite
NSample size (entire sample)
nSubgroup sample size
NANot applicable
NRNot reported
NSNot significant
NSDNo significant difference
OROdds ratio
PP value
PPlacebo
PCTPlacebo-controlled trial
PPYPer person year
PRIMUSPatient-Reported Indices for Multiple Sclerosis
qdOnce daily
QOLQuality of life
RCTRandomized controlled trial
RRRelative risk
SAESerious adverse event
SBSingle-blind
SDStandard deviation
SEStandard error
SRSustained release
tidThree times daily
URTIUpper respiratory tract infection
VASVisual analog scale
vs.Compared with (versus)
WDWithdrawal
XRExtended release
yYear
Copyright © 2011 by Oregon Health & Science University.
Cover of Drug Class Review: Disease-Modifying Drugs for Multiple Sclerosis: Single Drug Addendum: Fingolimod
Drug Class Review: Disease-Modifying Drugs for Multiple Sclerosis: Single Drug Addendum: Fingolimod: Final Original Report [Internet].
McDonagh M.
Portland (OR): Oregon Health & Science University; 2011 Feb.

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...